Calyxt Announces 1-for-5 Reverse Stock Split of Common Stock ROSEVILLE, Minn. , May 19, 2023 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT) ("Calyxt" or the "Company") today announced the results of the special meeting of its stockholders held on May 18, 2023 . At the special meeting, Calyxt's stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Class A common stock and Class... Read More

Proposed merger with Cibus Global Expected to Close in Q2 2023 1-for-10 reverse stock split executed Current customer projects under development are on track Evologic Technologies completed initial phase of project to scale production of Calyxt's Plant Cell Matrix™ and BioFactory TM technologies ROSEVILLE, Minn. , May 1, 2023 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today... Read More

ROSEVILLE, Minn. , April 24, 2023 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT) ("Calyxt" or the "Company") today announced that it has completed the previously announced reverse stock split of Calyxt's common stock, par value $0.0001 per share ("Common Stock"), at a ratio of 1-for-10. The reverse stock split was previously approved by the Company's stockholders at the annual meeting of shareholders on June 1, 2022 . Calyxt... Read More

ROSEVILLE, Minn. and SAN DIEGO , April 18, 2023 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that the registration statement on Form S-4, initially filed with the U.S. Securities and Exchange Commission ("SEC") by Calyxt on February 14, 2023 , and amended on April 14, 2023 (as amended, the "Registration... Read More

ROSEVILLE, Minn. , April 7, 2023 /PRNewswire/ -- Calyxt, Inc . (Nasdaq: CLXT) ("Calyxt" or the "Company") today announced that it will proceed with the 1-for-10 reverse stock split previously approved by the Company's shareholders at the annual meeting of shareholders on June 1 , 2022. Calyxt plans to file an amendment to its certificate of incorporation to effectuate the reverse stock split after the close of trading on... Read More

NEW YORK, March 06, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company for which Cellectis owns 49.1% (as of December 31, 2022) of its issued and outstanding common stock, today... Read More

Announced proposed merger with Cibus Global and filed initial registration statement on Form S-4 Current customer projects under development are on track Signed agreement with Evologic Technologies to further develop and scale production of its Plant Cell Matrix™ and BioFactory TM technologies ROSEVILLE, Minn. , March 2, 2023 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today... Read More

ROSEVILLE, Minn. and SAN DIEGO , Feb. 15, 2023 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that Calyxt has filed a registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission ("SEC") on February 14, 2023 . The combined company is expected to be renamed... Read More

NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its gene editing platform to deliver life-saving cell and gene therapies, announced today that Cibus Global LLC, a Delaware limited liability company (“Cibus”), and Calyxt, Inc. (NASDAQ: CLXT) (“Calyxt”), announced that Calyxt and Calypso Merger Subsidiary, LLC, a Delaware limited... Read More

The merger will bring together the technology platforms and facilities of two pioneering companies to create a leader in precision gene editing focused on driving sustainable agriculture and the availability of renewable low-carbon ingredients Upon closure of the merger, Rory Riggs , Cibus Co-Founder, will become Chief Executive Officer and Chairman of the combined company and the Cibus leadership team will lead the new... Read More

ROSEVILLE, Minn. , Nov. 18, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ: CLXT), a plant-based synthetic biology company announced today that it has successfully completed the first phase in its research collaboration agreement with a leading global food ingredient manufacturer based in Asia to develop an improved soybean capable of producing an oil as a commercial alternative to palm oil. "We are proud of the progress we've... Read More

ROSEVILLE, Minn. , Nov. 17, 2022 /PRNewswire/ -- Calyxt, Inc (Nasdaq: CLXT) a plant-based synthetic biology focused on engineering sustainable ingredients for customers in the cosmeceutical, nutraceutical and pharmaceutical industries, today announced that the Company received written notification from the Listing Qualifications Department of The Nasdaq Stock Market, LLC ("Nasdaq"), granting the Company's request for a... Read More

Successfully produced squalene, an important ingredient for personal care products and vaccine adjuvants Continued to progress customer acquisition activities, including evaluating an incremental 37 customer chemistries for development using PlantSpring™ and BioFactory™ technologies Signed agreement with Evologic Technologies to further develop and scale production of its Plant Cell Matrix™ technology platform Continuing... Read More

Calyxt joins a select network of synthetic biology companies, top-tier academic institutions, research-focused not-for-profits, and US government agencies dedicated to innovating and growing the bioeconomy Calyxt, Inc. (NASDAQ: CLXT), a plant-based synthetic biology company, announced today that it has become a member of Bioindustrial Manufacturing and Design Ecosystem (BioMADE), a Department of Defense initiated... Read More

Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, will host a conference call and webcast on Thursday, November 3, 2022 , at 4:30 p.m. ET to discuss results for the third quarter ended September 30, 2022 . A press release detailing these results will be issued prior to the call. President and Chief Executive Officer, Michael A. Carr , and Chief Financial Officer, Bill Koschak , will host the conference... Read More

Calyxt, Inc. (NASDAQ: CLXT), a plant-based synthetic biology company, announced today that using a Calyxt-engineered Plant Cell Matrix™ biomass, it has successfully produced squalene, an important ingredient in many personal care products and vaccine adjuvants, including several strands of flu and COVID-19 vaccines. Leveraging the power of its PlantSpring™ technology platform, Calyxt's plant-based squalene is a natural... Read More

Agreement will power speed-to-scale strategy to meet the growing interest in high-quality sustainable ingredients across the cosmeceutical, nutraceutical and pharmaceutical markets Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced that it has signed an agreement with its first manufacturing partner, Evologic Technologies GmbH, to further develop and scale Calyxt's proprietary Plant Cell... Read More

Calyxt, Inc. (NASDAQ: CLXT) ("Calyxt"), a plant-based synthetic biology company, today announced that its Board of Directors is evaluating potential strategic alternatives to maximize shareholder value. As part of the process, the Board is considering a full range of strategic alternatives, which may include financing alternatives, merger, reverse merger, other business combinations, sale of assets, licensing, or other... Read More

Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced that Michael A. Carr , President and Chief Executive Officer, and Bill Koschak , Chief Financial Officer, will present at the H.C Wainwright 24 th Annual Global Investment Conference taking place September 12-14, 2022 . H.C. Wainwright 24 th Annual Global Investment Conference Date: Tuesday, September 13, 2022 Time: 2:30 p.m. ET Webcast:... Read More

Evaluated nine new customer demand-driven plant-based chemistries in the quarter, bringing cumulative chemistries evaluated for development to 95, of these 31 meet Calyxt's target profile and several are the subject of term sheet discussions Engineering solution for a high-value molecule planned to be delivered in early 2023 to a large global consumer packaged goods company Progressing discussions with multiple potential... Read More

Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced that Michael A. Carr , Chief Executive Officer, and Bill Koschak , Chief Financial Officer, will present at the Canaccord Genuity 42 nd Annual Growth Conference taking place August 8-11, 2022 . The presentation details are as follows: Date: Thursday, August 11, 2022 Presentation Time: 1:00 p.m. ET Webcast:... Read More

Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, will host a conference call and webcast on Thursday, August 4, 2022 , at 4:30 p.m. Eastern Time to discuss results for the second quarter ended June 30, 2022 . A press release detailing these results will be issued prior to the call. President and Chief Executive Officer, Michael A. Carr , and Chief Financial Officer, Bill Koschak , will host the... Read More

Calyxt , Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced that management will participate in the following upcoming investor conferences: H.C. Wainwright Global Investment Conference Date: May 25, 2022 Time: 11:30 am ET Webcast: https://journey.ct.events/view/dd5ae7e1-6b52- 430b -b9d8-504d330d80ad LD Micro Invitational (XII) Date: June 8, 2022 Time: 7:30 am ET Webcast:... Read More

Achieved technical BioFactory™ and AIML milestones to support customer demand-driven molecule development at scale Progressed relationships with an expanding network of potential new customers across the cosmeceutical and flavor and fragrance end markets Continued investment in key hires to strategically position Company for... Read More

Continued investment in key hires to strategically position Company for future growth and scale Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biotechnology company, yesterday welcomed the second of two director-level hires in areas critical to the continued advancement of the Company's key technology and business... Read More

Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, will host a conference call and webcast on Thursday, May 5, 2022 , at 4:30 p.m. Eastern Time to discuss results for the first quarter ended March 31, 2022 . A press release detailing these results will be issued prior to the call. President and Chief... Read More

Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced that management will participate in a fireside chat at the 34 th Annual Roth Conference at the Ritz-Carlton in Dana Point, CA. 34 th Annual Roth Conference Date: Tuesday, March 15, 2022 Time: 3:00 p.m. ET ( 12:00 p.m. PT ) Webcast:... Read More

Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced financial results for its fourth quarter and full year ended December 31, 2021 . "Last year was transformational for Calyxt, as we evolved our strategic direction to focus our innovations on plant-based technology and production for new... Read More

Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, will hold a conference call on Thursday, March 3, 2022 , at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter and full year ended December 31, 2021 . A press release detailing these results will be issued prior to the call. President and... Read More

Calyxt, Inc. (NASDAQ: CLXT) ("Calyxt" or the "Company"), a plant-based synthetic biology company, today announced the closing of its previously announced placement to an institutional investor in an underwritten offering of 3,880,000 shares of its common stock, pre-funded warrants to purchase up to 3,880,000 shares of its... Read More

Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, and Calyxt, Inc. (“Calyxt”), a majority-owned (61.8% as of December 31, 2021) subsidiary of Cellectis S.A., announced the placement to an institutional investor in an underwritten offering of (i) 3,880,000 shares of Calyxt common stock, (ii)... Read More

Calyxt, Inc. (NASDAQ: CLXT) ("Calyxt" or the "Company"), a plant-based synthetic biology company, today announced the placement to an institutional investor in an underwritten offering of 3,880,000 shares of its common stock, pre-funded warrants to purchase up to 3,880,000 shares of its common stock, and common warrants to purchase up to 7,760,000 shares of its common stock (the "Offering"). The shares of common stock and... Read More

Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biotechnology company, today announced that Gerry Nuovo has joined Calyxt as Senior Vice President of Business Development. He brings more than 30 years of experience in the specialty chemicals and biotechnology industries and diverse experience building multimillion-dollar... Read More

Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biotechnology company, today announced that its pilot BioFactory™ production system, installed in late December 2021 , is now operational at its headquarters site in Minnesota . "I am proud of the effort our team and suppliers made to achieve this milestone on schedule, as... Read More

Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biotechnology company today announced that a presentation given by management at the H.C Wainwright BioConnect Conference will be available for viewing online on Monday, January 10, 2022 at 7:00 a.m. ET . The conference will be held in a virtual meeting format. H.C.... Read More

Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biotechnology company, today announced the completion of a key milestone in its lab-scale BioFactory™ manufacturing system. The results identified through the Company's metabolomics analyses indicate over 15,000 chemical signatures, including both known and... Read More

Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biotechnology company, today announced the hiring of two senior roles important to furthering Calyxt's recently announced strategic direction. Joining the Company are Vijay Gullapalli , Ph.D., as Vice President, Artificial Intelligence/Machine Learning (AI/ML) and Data... Read More

Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biotechnology company, today announced that management will present at the 2021 Canaccord Genuity AgriFood Tech Innovation Virtual Forum. 2021 Canaccord Genuity AgriFood Tech Innovation Virtual Forum Date: Thursday, December 2, 2021 Time: 11:00 a.m. ET ( 8:00 a.m. PT ) Webcast: https://wsw.com/webcast/canaccord62/clxt/2475458 The presentation will be available for viewing... Read More

Calyxt, Inc. (NASDAQ: CLXT), a plant-based synthetic biotechnology company, today announced financial results for its third quarter ended September 30, 2021 . "Since I joined the Company as CEO in July, Calyxt has made significant progress, aligning on a new strategic direction that leverages our Company's strengths and key areas of differentiation, and positions Calyxt as a synthetic biology company in its own right," said... Read More

Calyxt, Inc. (Nasdaq: CLXT) will hold a conference call on Thursday, November 4, 2021 , at 4:30 p.m. Eastern time to discuss its results for the third quarter ended on September 30, 2021 . A press release detailing these results will be issued prior to the call. Chief Executive Officer Michael A. Carr and Chief Financial Officer Bill Koschak will host the conference call, followed by a question-and-answer session. The... Read More

Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biotechnology company, today announced the appointment of Seth Dobrin , Ph.D., to the Company's Scientific Advisory Board (SAB). Dr. Dobrin is the Global Chief Artificial Intelligence (AI) Officer at IBM and brings extensive leadership experience and a track record of transforming companies through data and AI. "We warmly welcome Seth to our Scientific Advisory Board. Seth... Read More

Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biotechnology company, today announced the launch of a strategic initiative that will focus the Company on engineering synthetic biology solutions for a diversified base of customers across an expanded group of end markets including the nutraceutical, cosmeceutical,... Read More

Calyxt, Inc. (Nasdaq: CLXT), a plant-based technology platform company, today announced it entered into a research collaboration with a leading global food ingredient manufacturer based in Asia to develop an improved soybean capable of producing an oil as a commercial alternative to palm oil. In addition to the potential health benefits, this soybean and its oil may address sustainability challenges associated with palm oil,... Read More

Calyxt, Inc. (NASDAQ: CLXT), a plant-based technology platform company, today announced that a presentation given by management at the H.C Wainwright 23 rd Annual Global Investment Conference will be available for viewing online on September 13 th at 7:00 a.m. ET . The conference will be held in a virtual meeting format. H.C.... Read More

Calyxt, Inc. (NASDAQ: CLXT), a plant-based technology company, today announced financial results for its second quarter ended June 30, 2021 . "We made significant progress in the second quarter, notably appointing Michael A. Carr as President and Chief Executive Officer where he will lead us in our efforts to advance the... Read More

Calyxt, Inc. (Nasdaq: CLXT), a plant-based biotechnology platform company, today announced that management will present at the Canaccord Genuity 41st Annual Growth Conference at 11:00 a.m. ET . The conference will be held in a virtual meeting format. Canaccord Genuity 41st Annual Growth Conference Date: Wednesday, August 11,... Read More

Calyxt, Inc. (NASDAQ: CLXT), a plant-based biotechnology platform company, today announced that, in accordance with the offer letter entered into on July 15, 2021 , it has granted, effective July 27, 2021 (the "Grant Date"), an inducement award to Michael A. Carr , Calyxt's newly appointed President and Chief Executive Officer. Mr. Carr received an award of performance stock units ("PSUs") to acquire up to 600,000 shares of... Read More

Calyxt, Inc. (NASDAQ: CLXT) will hold a conference call on Thursday, August 5, 2021 at 4:30 p.m. Eastern time to discuss its results for the second quarter ended on June 30, 2021 . A press release detailing these results will be issued prior to the call. Calyxt Executive Chair Dr. Yves Ribeill , President and Chief Executive... Read More

Calyxt, Inc. (NASDAQ: CLXT), a plant-based biotechnology platform company, today announced the appointment of Michael A. Carr as President and Chief Executive Officer, effective July 27, 2021 . Mr. Carr will also serve as a member of Calyxt's Board of Directors. Mr. Carr was most recently the Vice President of M&A, Strategy, and Innovation at Darling Ingredients, Inc., a global developer and producer of sustainable natural... Read More

Triploid Breeding Process is Calyxt's Second Announced Advancement and Part of a Comprehensive Approach to Improving Hemp Genetics Calyxt, Inc. (NASDAQ:CLXT), today announced further expansion of its hemp breeding platform with the addition of triploid breeding technology to create seedless hemp. Bringing this technology to hemp cultivation comes on the heels of the company announcing the successful transformation of the... Read More

Early-Stage Validation that Next Generation Premium Soybean Product Performance is Best-in-Class for High Oleic, Ultra-Low Linolenic Profile Successful Transformation of Hemp Genome Enables Step Change in Calyxt's Innovation Approaches in the Species Promoted Sarah Reiter to the newly created role of Chief Business Officer Scientific Advisory Board Formed, Diverse Scientific Expertise, and Proprietary Insights to Support... Read More

Next Generation Premium Soybean Product Line Contains Ultra-Low Levels of Linolenic Acid Positioning it to be the Most Stable Premium Soybean Oil Available on the Market R&D Advancement with Complex Plant Biological Pathways Enables Calyxt to Deliver Next Generation Plant-Based Solutions in Rapid Time Frame Calyxt, Inc. (NASDAQ:CLXT), a plant-based technology company, announced today that its next generation premium high... Read More

New Hemp Transformation Technology Unlocks Capabilities to Selectively Breed and Deliver Improvements in Hemp Traits for Key Markets Including Protein, Fiber, Advanced Materials and Wellness Patent-Pending Transformation Process is Calyxt's First Announced Innovation in a Broad Hemp Improvement Pipeline Calyxt, Inc. (NASDAQ:CLXT), a plant-based technology company, announced today that it has successfully transformed hemp... Read More

Calyxt, Inc . (NASDAQ:CLXT), a plant-based technology company, will participate in the following investor and industry conferences during the month of May 2021: 2021 American Oil Chemists Society (AOCS) Annual Meeting & Expo Date: May 4, 2021 Time: 4:00 p.m. Central Format: Featured Session Presenter: Travis Frey, Ph.D., Chief Technology Officer Conference website here Oppenheimer 6th Annual Emerging Growth Conference Date:... Read More

Calyxt to Host First Quarter 2021 Financial Results Conference Call on Thursday, May 6, 2021 at 4:30 p.m. Eastern Time Calyxt, Inc. (NASDAQ:CLXT), a plant-based technology company, will hold a conference call on Thursday, May 6, 2021 at 4:30 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2021. A press release detailing these results will be issued prior to the call. Calyxt Executive Chairman... Read More

Continued to Progress Development of Winter Oats and Hemp, Both Targeted at Large Addressable Markets Secured Commitment from ADM to Purchase Remaining 2019 Grain Inventory and All 2020 Grain Production - Have Completed Sale of 40 Percent of 2020 Grain Crop Executed Commercial Agreement with S&W Seed Company on IQ™ Alfalfa... Read More

Calyxt, Inc. (NASDAQ:CLXT), a plant-based technology company, will participate in the following investor conferences during the month of March 2021: Bank of America Securities 2021 Global Agriculture & Materials Virtual Conference Date: Wednesday, March 3, 2021 Time: 11:00 a.m. Eastern time (8:00 a.m. Pacific time) Format: Gene Editing Panel Presentation Speaker: Dan Voytas, Ph.D. Calyxt Co-Founder & Scientific Advisory... Read More

World-Renowned Plant-Biochemistry Experts Named to Calyxt's Scientific Advisory Board Chaired by Company Co-Founder Dan Voytas, Ph.D. New Strategic Initiative to Identify High Value Plant-Derived Products Utilizing Calyxt's Proprietary Innovation Platform Calyxt, Inc. (NASDAQ:CLXT), a plant-based technology company, has completed key appointments to its previously announced Scientific Advisory Board (SAB) to identify high... Read More

Calyxt Secures its First Seed Distribution Agreement Since Advancing Business Model Calyxt, Inc. (NASDAQ:CLXT), a plant-based technology company, announced today that it has signed a non-exclusive seed distribution agreement with Perdue AgriBusiness, an independent operating company of Perdue Farms. Per the terms of the agreement, Perdue AgriBusiness will buy seed starting in the 2021 planting season. Under the seed... Read More

Calyxt, Inc. (NASDAQ:CLXT), a plant-based technology company, today announced that the Board of Directors has appointed Yves Ribeill, Ph.D., to the new role of Executive Chair of the Board effective immediately. Dr. Ribeill will serve in this role while Calyxt initiates a search for a new Chief Executive Officer to replace Jim Blome, who is leaving to pursue other opportunities. Calyxt has retained a premier executive search... Read More

Calyxt, Inc . (NASDAQ: CLXT), a plant-based technology company, will hold a conference call on Thursday, March 4, 2021 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2020. A press release detailing these results will be issued prior to the call. Calyxt Chief Executive Officer Jim Blome and Chief Financial Officer Bill Koschak will host the conference call, followed by... Read More